Dernière mise à jour :
24/02/2017
Stabilité et compatibilité des médicaments
Bienvenue dans Stabilis.
Si vous désirez recevoir la newsletter trimestrielle, indiquez votre adresse email.

Pour toute question ou remarque, contactez : infostab@stabilis.org
Base de données  
Références bibliographies : 2128
Molécules : 765
Classes pharmacologiques : 40
Stabilités en solution : 4688
Stabilités en mélange : 992
Incompatibilités : 2904
Noms commerciaux : 1963
Nouveautés - Molécules  
Anticancéreux Injectable Necitumumab 31/01/2017
Divers Injectable Belimumab 24/01/2017
Hypoglycémiant Injectable Insulin glulisine 24/01/2017
Divers Injectable Zoledronic acid 24/01/2017
Antidote Injectable Hydroxocobalamin 24/01/2017
Divers Injectable Trimebutine 24/01/2017
Divers Injectable Indocyanine green 24/01/2017
Stimulant respiratoire Solution buvable Caffeine 23/01/2017
Antiinflammatoire Solution buvable Naproxen 22/01/2017
Antidépresseur Solution buvable Sertraline hydrochloride 22/01/2017
Antiémétique Solution buvable Domperidone 22/01/2017
Antiépileptique Solution buvable Carbamazepine 22/01/2017
Divers Solution buvable Allopurinol 22/01/2017
Antidépresseur Solution buvable Clomipramine 22/01/2017
Antiarythmique Solution buvable Nadolol 22/01/2017
Antibiotique Solution buvable Clindamycine hydrochloride 11/01/2017
Inhibiteur de la pompe à proton Solution buvable Esomeprazole magnesium trihydrate 11/01/2017
Divers Injectable Plerixafor 28/11/2016
Hypoglycémiant Solution buvable Glibenclamide 18/11/2016
Vasodilatateur Forme dermique Nitroglycérine 09/11/2016
Nouveautés - Références bibliographies  
Date de saisie
3941 Nicardipine - Summary of Product Characteristics Concordia International 21/02/2017
3938 Necitumumab (Portrazza®) – Résumé des caractéristiques du produits Lilly S.A 31/01/2017
3930 Indocyanine (Infracyanine®) - Résumé des caractéristiques du produit Serb laboratoire 24/01/2017
3931 Trimébutine (Débridat®) - Résumé des caractéristiques du produit Pfizer Laboratoire 24/01/2017
3932 Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 24/01/2017
3933 Acide zolédronique - (Acide zoledronique Teva Pharma®) - Résumé des caractéristiques du produit Teva Laboratoire 24/01/2017
3934 Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 24/01/2017
3935 Insuline glulisine (Insulines Sanofi Apidra®) - Résumé des caractéristiques du produit Sanofi Laboratoire 24/01/2017
3936 Bélimumab (Benlysta®) – Résumé des caractéristiques du produits GlaxoSmithKline Laboratoire 24/01/2017
3913 Compatibility of proton pump inhibitors in a preservative-free suspending vehicle. EJHP 03/12/2016
3910 Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. EJHP 31/10/2016
3901 Stability of Clindamycin Hydrochloride in PCCA Base SuspendIt Int J Pharm Compound 06/10/2016
3902 Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions. Int J Pharm Compound 06/10/2016
3895 Physicochemical Stability Study of Polymyxin B in Various Infusion Solutions for Administration to Critically Ill Patients Ann Pharmacotherapy 06/09/2016
3896 Physicochemical Stability of Mozobil® (Plerixafor) Solution for Injection in Glass Vials and Plastic Syringes over a Three-Month Storage Period Pharmaceutical Technology in Hospital Pharmacy 06/09/2016
3897 Stability of Reconstituted and Diluted Mitomycin C Solutions in Polypropylene Syringes and Glass Vials. Pharmaceutical Technology in Hospital Pharmacy 06/09/2016
3898 Chemical and microbiological stability studies of an aqueous solution of pravastatin sodium salt for drug therapy of the dysphagic patients EJHP 06/09/2016
3892 Stability of Hydrocortisone, Nifedipine, and Nitroglycerine Compounded Preparations for the Treatment of Anorectal Conditions Can J Hosp Pharm 31/08/2016
3893 Stability of Extemporaneously Compounded Amlodipine Besylate Oral Suspensions Can J Hosp Pharm 31/08/2016
3891 Stability of Ertapenem 100 mg/mL in Manufacturer’s Glass Vials or Syringes at 4°C and 23°C Can J Hosp Pharm 16/08/2016
3879 Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 03/08/2016
3880 Stability of Ampicillin in Normal Saline and Buffered Normal Saline. Int J Pharm Compound 03/08/2016
3881 Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump. Int J Pharm Compound 03/08/2016
3885 Diazepam sorption to PVC- and non-PVC-based tubes in administration sets with quantitative determination using a high-performance liquid chromatographic method. Int J Pharm 03/08/2016
3886 Design and stability study of an oral solution of amlodipine besylate for pediatric patients. Eur J Pharm Sci 03/08/2016
3887 Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 03/08/2016
3888 Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study). Perit Dial Int 03/08/2016
3873 Incompatibility between irinotecan and fluorouracil injections Am J Health-Syst Pharm 27/07/2016
3874 Long-term stability of ketamine hydrochloride 50 mg/ml injection in 3 ml syringes Ann Pharm Fr 27/07/2016
3875 Development and stability study of glibenclamide oral liquid paediatric formulations for the treatment of permanent neonatal diabetes mellitus. EJHP 27/07/2016

Temps de calcul serveur : 91 millisecondes